Personalized drug therapy; the genome, the chip and the physician

被引：13
作者：
Lewis, LD
机构：
[1] Dartmouth Coll Sch Med, Dept Med, Clin Pharmacol Sect, Lebanon, NH 03756 USA
[2] Dartmouth Hitchcock Med Ctr, Lebanon, NH 03756 USA
来源：
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY | 2005年 / 60卷 / 01期
关键词：
D O I：
10.1111/j.1365-2125.2005.02457.x
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：1 / 4
页数：4
相关论文
共 35 条
[1]   A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin [J].
D'Andrea, G ;
D'Ambrosio, RL ;
Di Perna, P ;
Chetta, M ;
Santacroce, R ;
Brancaccio, V ;
Grandone, E ;
Margaglione, M .
BLOOD, 2005, 105 (02) :645-649
[2]   Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid [J].
Dai, D ;
Zeldin, DC ;
Blaisdell, JA ;
Chanas, B ;
Coulter, SJ ;
Ghanayem, BI ;
Goldstein, JA .
PHARMACOGENETICS, 2001, 11 (07) :597-607
[3]   Pharmacogenetics of oral anticoagulants [J].
Daly, AK ;
King, BP .
PHARMACOGENETICS, 2003, 13 (05) :247-252
[4]   Pharmacogenetics of the cytochromes P450 [J].
Daly, AK .
CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2004, 4 (16) :1733-1744
[5]   CYP2C9 polymorphism and warfarin dose requirements [J].
Daly, AK ;
Day, CP ;
Aithal, GP .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2002, 53 (04) :408-409
[6]  
Dickson Euan J, 2003, Am J Pharmacogenomics, V3, P303, DOI 10.2165/00129785-200303050-00002
[7]   Moving towards individualized medicine with pharmacogenomics [J].
Evans, WE ;
Relling, MV .
NATURE, 2004, 429 (6990) :464-468
[8]   Pharmacogenomics: The inherited basis for interindividual differences in drug response [J].
Evans, WE ;
Johnson, JA .
ANNUAL REVIEW OF GENOMICS AND HUMAN GENETICS, 2001, 2 :9-39
[9]   Cure of refractory duodenal ulcer and infection caused by Helicobacter pylori by high doses of omeprazole and amoxicillin in a homozygous CYP2C19 extensive metabolizer patient [J].
Furuta, T ;
Takashima, M ;
Shirai, N ;
Xiao, F ;
Hanai, H ;
Ohashi, K ;
Ishizaki, T .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2000, 67 (06) :684-689
[10]   Therapeutic impact of CYP2C19 pharmacogenetics on proton pump inhibitor-based eradication therapy for Helicobacter pylori [J].
Furuta, T ;
Shirai, N ;
Ohashi, K ;
Ishizaki, T .
METHODS AND FINDINGS IN EXPERIMENTAL AND CLINICAL PHARMACOLOGY, 2003, 25 (02) :131-143
1234